Peer-influenced content. Sources you trust. No registration required. This is HCN.

FDA Approves Nivolumab for Treatment of Certain Patients With ESCC

Based on the data from the ATTRACTION-3 clinical trial, the FDA approved nivolumab (Opdivo; BMS) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who previously received fluoropyrimidine- and platinum-based chemotherapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form